Author Of 1 Presentation
LB1214 - Antiviral activity of Interferon beta-1b to SARS-CoV-2 infection (ID 2078)
Abstract
Background
SARS-CoV-2, is a new coronavirus (CoV), which is spreading all over the world, since it was identified in a group of people with pneumonia of an unknown cause at Wuhan, province of Hubei, China. At the present time, it is working hard in a vaccine development and in the searching of medical treatments with the purpose of improving the prognosis of those cases that get the infection. Nowadays, neurologists treating patients with Multiple Sclerosis (MS) face the uncertainty of the impact that this new disease may generate.
Objectives
To assess whether interferons can play a protective or therapeutically important role in patients infected with SARS-CoV-2
Methods
Recently we have seen the case of a 68 years of age patient with a diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) under Interferon beta-1b treatment since the illness diagnosis has been received 8 years ago. She shows history of hypertension with the pharmacological treatment and resides at a geriatric together with other 20 people (all of them older than 65 five years old) and 4 nurses for her assistance. Since the preventive social isolation was ruled in Argentina, residents at the geriatrics do not receive their family visits and at the situation of a medical examination, this was accomplished with the protection protocols. During the month of July of this year, a male resident of the same institution experienced fever and cough (48 hours before he had been discharged from a hospital), so he was transferred to another hospital and a swab (oropharyngeal and nasal) was carried out suspecting CoV, resulting the same positive.
Results
It was decided to swab the 25 people that reside at the geriatric. From the 4 nurses 2 were positive and from the 20 older adults’ residents, 19 obtained a positive result except the patient under MS diagnosis in treatment with Interferon beta-1b. All of them were hospitalize because of age and comorbidities, 4 died and 16 are still hospitalized. They are stable but a second swab resulted positive (at the month of August). Our patient has never developed fever nor any other symptomatology, her breathing rate and oxygen saturation were always normal.
Conclusions
We can conclude that nowadays, the Interferon beta-1b still is a good option for the treatment of MS patients, especially during this difficult pandemic period and time will tell us if additionally this molecule may fulfill a role of therapeutic importance in patients infected with SARS-CoV-2.
Presenter Of 1 Presentation
LB1214 - Antiviral activity of Interferon beta-1b to SARS-CoV-2 infection (ID 2078)
Abstract
Background
SARS-CoV-2, is a new coronavirus (CoV), which is spreading all over the world, since it was identified in a group of people with pneumonia of an unknown cause at Wuhan, province of Hubei, China. At the present time, it is working hard in a vaccine development and in the searching of medical treatments with the purpose of improving the prognosis of those cases that get the infection. Nowadays, neurologists treating patients with Multiple Sclerosis (MS) face the uncertainty of the impact that this new disease may generate.
Objectives
To assess whether interferons can play a protective or therapeutically important role in patients infected with SARS-CoV-2
Methods
Recently we have seen the case of a 68 years of age patient with a diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) under Interferon beta-1b treatment since the illness diagnosis has been received 8 years ago. She shows history of hypertension with the pharmacological treatment and resides at a geriatric together with other 20 people (all of them older than 65 five years old) and 4 nurses for her assistance. Since the preventive social isolation was ruled in Argentina, residents at the geriatrics do not receive their family visits and at the situation of a medical examination, this was accomplished with the protection protocols. During the month of July of this year, a male resident of the same institution experienced fever and cough (48 hours before he had been discharged from a hospital), so he was transferred to another hospital and a swab (oropharyngeal and nasal) was carried out suspecting CoV, resulting the same positive.
Results
It was decided to swab the 25 people that reside at the geriatric. From the 4 nurses 2 were positive and from the 20 older adults’ residents, 19 obtained a positive result except the patient under MS diagnosis in treatment with Interferon beta-1b. All of them were hospitalize because of age and comorbidities, 4 died and 16 are still hospitalized. They are stable but a second swab resulted positive (at the month of August). Our patient has never developed fever nor any other symptomatology, her breathing rate and oxygen saturation were always normal.
Conclusions
We can conclude that nowadays, the Interferon beta-1b still is a good option for the treatment of MS patients, especially during this difficult pandemic period and time will tell us if additionally this molecule may fulfill a role of therapeutic importance in patients infected with SARS-CoV-2.